107 148
is still an unequalled source of data. Although this registry
study suffers from many shortcomings, waiting period
should not be modified for high-risk renal and PCs.
Urothelial carcinomas are multifocal and highly recurrent
tumours. For transplantation candidates, close follow-up or
systematic bilateral nephroureterectomy are both possible
strategies. For patients with a history of TC a case-by-case
discussion is recommended.
Author contributions:
Alberto Breda had full access to all the data in the
study and takes responsibility for the integrity of the data and the
accuracy of the data analysis.
Study concept and design:
Boissier, Hevia, Bruins, Budde, Figueiredo,
Lledó-García, Olsburgh, Regele, Taylor, Zakri, Yuan, Breda.
Acquisition of data:
Boissier, Hevia, Bruins, Yuan.
Analysis and interpretation of data:
Boissier, Hevia, Bruins.
Drafting of the manuscript:
Boissier.
Critical revision of the manuscript for important intellectual content:
Boissier, Hevia, Bruins, Budde, Figueiredo, Lledó-García, Olsburgh,
Regele, Taylor, Zakri, Yuan, Breda.
Statistical analysis:
None.
Obtaining funding:
None.
Administrative, technical, or material support:
Yuan.
Supervision:
Breda.
Other:
None.
Financial disclosures:
Alberto Breda certi
fi
es that all con
fl
icts of interest,
including speci
fi
c
fi
nancial interests and relationships and af
fi
liations
relevant to the subject matter or materials discussed in the manuscript
(eg, employment/af
fi
liation, grants or funding, consultancies, honoraria,
stock ownership or options, expert testimony, royalties, or patents
fi
led,
received, or pending), are the following: None.
Funding/Support and role of the sponsor:
This study was supported by
the European Association of Urology. The European Association of
Urology had no role in the design and conduct of the study, collection,
management, analysis, and interpretation of the data, preparation,
review, or approval of the manuscript nor the decision to submit the
manuscript for publication.
Acknowledgments:
The valuable help of European Association of Urology
Guidelines Of
fi
ce, Arnhem, Netherlands in providing the full text articles
and administrative support is gratefully acknowledged. Furthermore, we
thank Thomas Lamand Cathy Yuhong Yuan of the European Association
of Urology Guidelines Of
fi
ce Methods Committee, for providing
methodological support.
Appendix A. Supplementary data
Supplementary data associated with this article can be
found, in the online version, at
http://dx.doi.org/10.1016/j. eururo.2017.07.017 .References
[1]
Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996;50:235 – 42.
[2]
Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a fi rst cadaveric transplant. N Engl J Med 1999;341:1725 – 30.[3]
Kälble T, Lucan M, Nicita G, et al. EAU guidelines on renal trans- plantation. Eur Urol 2005;47:156 – 66.
[4]
Penn I. Evaluation of transplant candidates with pre-existing ma- lignancies. Ann Transplant 1997;2:14 – 7.[5]
Moher D, Liberati A, Tetzlaff J, Altman DG, PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
[6] Higgins JPT. Green S. Cochrane handbook for systematic reviews of
interventions version 5.1. 0.
http://training.cochrane.org/handbook.
[7]
Reeves BC, Deeks JJ, Higgins JP.13 Including nonrandomized studies. Cochrane Handb Syst Rev Interv 2008;1:391.
[8]
Dean C, Bloom fi eld D, Holt S. The challenge of germ cell tumour therapy in dialysis and transplantation. Nephrol Dial Transplant 2005;20:2867 – 8.
[9]
Woodle ES, Gupta M, Buell JF, et al. Prostate cancer prior to solid organ transplantation: the Israel Penn International Transplant Tumour Registry experience. Transplant Proc 2005;37:958 – 9.
[10]
Viecelli AK, LimWH, Macaskill P, et al. Cancer-speci fi c and all-cause mortality in kidney transplant recipients with and without previous cancer. Transplantation 2015;99:2586 – 92.
[11]
Brattström C, Granath F, Edgren G, Smedby KE, Wilczek HE. Overall and cause-speci fi c mortality in transplant recipients with a pre- transplantation cancer history. Transplantation 2013;96:297 – 305.[12]
Farivar-Mohseni H, Perlmutter AE, Wilson S, Shingleton WB, Bigler SA, Fowler JE. Renal cell carcinoma and end stage renal disease. J Urol 2006;175:2018 – 20, discussion 2021.
[13]
Ishikawa I. Acquired cystic disease of the kidney and renal cell carcinoma-complication of long-term hemodialysis. In: Acquired cystic disease of the kidney and renal cell carcinoma-complication of long-term hemodialysis. Japan: Springer; 2007.[14]
Breda A, Lucarelli G, Luccarelli G, et al. Clinical and pathological outcomes of renal cell carcinoma (RCC) in native kidneys of patients with end-stage renal disease: a long-term comparative retrospec- tive study with RCC diagnosed in the general population. World J Urol 2015 Jan;33:1 – 7.
[15]
Neuzillet Y, Tillou X, Mathieu R, et al. Renal cell carcinoma (RCC) in patients with end-stage renal disease exhibits many favourable clinical, pathologic, and outcome features compared with RCC in the general population. Eur Urol 2011;60:366 – 73.
[16]
Gigante M, Neuzillet Y, Patard J-J, et al. Renal cell carcinoma (RCC) arising in native kidneys of dialyzed and transplant patients: are they different entities? BJU Int 2012;110:E570 – 3.
[17]
Butler AM, Olshan AF, Kshirsagar AV, et al. Cancer incidence among US Medicare ESRD patients receiving hemodialysis, 1996-2009. Am J Kidney Dis 2015;65:763 – 72.
[18]
Mottet N, Bellmunt J, Bolla M, et al. EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part 1: screening, diagnosis, and local treatment with curative intent. Eur Urol 2017;71:618 – 29.
[19]
Breyer BN, Whitson JM, Freise CE, Meng MV. Prostate cancer screen- ing and treatment in the transplant population: current status and recommendations. J Urol 2009;181:2018 – 25, discussion 2025 – 6.
[20]
Wu C-F, Chang P-L, Chen C-S, Chuang C-K, Weng H-H, Pang S-T. The outcome of patients on dialysis with upper urinary tract transition- al cell carcinoma. J Urol 2006;176:477 – 81.[21]
Kang C-H, Chen C-H, Chiang P-H. Primary urothelial carcinoma of the upper urinary tract in dialysis patients with 5-year follow-up. Jpn J Clin Oncol 2010;40:241 – 6.
[22]
Rouprêt M, Babjuk M, Compérat E, et al. European Association of Urology Guidelines on Upper Urinary Tract Urothelial Cell Carcino- ma: 2015 update. Eur Urol 2015;68:868 – 79.
[23]
Sheashaa HA, Rennke HG, Bakr MA, et al. Impact of accidental discovery of renal cell carcinoma at time of renal transplantation on patient or graft survival. Transplantation 2011;92:1123 – 8.
[24]
Denton MD, Magee CC, Ovuworie C, et al. Prevalence of renal cell carcinoma in patients with ESRD pre-transplantation: a pathologic analysis. Kidney Int 2002;61:2201 – 9.E U R O P E A N U R O L O GY 7 3 ( 2 0 18 ) 9 4
–
10 8
107